LYKA LABS
|
The Current P/E Ratio of LYKA LABS is 114.95.
| Share Price | ₹81.0 | Nov 28,2025 |
| Market Cap | ₹289.2 Cr | |
| Earnings-TTM | ₹2.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 114.95x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LYKA LABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹289.2 Cr] as on Nov 28,2025
(/) Earnings [ ₹2.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 114.95x ]
Thus, for LYKA LABS , the investors are currently willing to pay 114.95 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LYKA LABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LYKA LABS over the last five years.
Historical PE (Price/Earnings) ratio chart of LYKA LABS
PE Ratio Performance Analysis for LYKA LABS
- LYKA LABS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 10.99x.
- LYKA LABS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LYKA LABS 's p/e ratio peaked in Mar2025 at 44.97x.
- LYKA LABS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does LYKA LABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LYKA LABS | 2.52 | 114.95 | 289.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 41.77 | 439,378.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 69.21 | 171,996.0 |
| CIPLA LTD | 5,453.86 | 22.67 | 123,666.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 58.86 | 125,959.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.35 | 105,008.0 |
| MANKIND PHARMA LTD | 1,767.06 | 52.61 | 92,957.5 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 19.06 | 94,812.4 |
| LUPIN LTD | 4,347.53 | 21.86 | 95,052.2 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.62 | 71,084.3 |
| ABBOTT INDIA LTD | 1,508.95 | 42.34 | 63,895.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LYKA LABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.35x |
| Max industry PE | 114.95x |
| Median industry PE | 41.77x |
| Average industry PE | 43.85x |
You may also like the below Video Courses